The Nanosonics Ltd (ASX: NAN) share price is in focus today after the company posted FY26 revenue of $203.9 million, up 3% on the prior year, and reported strong growth in trophon unit placements and successful launches of next-generation devices.

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital

Image source: Getty Images

What did Nanosonics report?

  • Revenue increased 3% on prior corresponding period (pcp) to $203.9 million, or 6% on a constant currency basis to $211.5 million
  • EBIT came in at $16.0 million, down 10% on pcp, but up 21% to $21.6 million at constant currency
  • trophon-only EBIT was $50.6 million, a 5% increase on pcp (16% at constant currency)
  • Total trophon unit placements rose 9% to 4,230 units, with global installed base up 6% to 39,230 devices
  • Cash and cash equivalents stood at $155.2 million as at 30 June 2026, and the company remains debt free
  • $20 million share buyback completed, with a new buyback of up to $40 million announced for FY27

What else do investors need to know?

Nanosonics launched its next generation trophon3 and trophon2 Plus systems during FY26, seeing accelerating adoption in the second half of the year. North America was a key driver, with record device upgrades up 32% on last year.

The company continued making headway with the CORIS System, progressing through a Controlled Market Release and receiving favourable customer feedback. Regulatory milestones were achieved, including approvals in major markets and FDA clearances.

What did Nanosonics management say?

CEO and President said Michael Kavanagh said:

Nanosonics is entering a defining period of growth. FY26 demonstrated the strength of the business we have built: a proven trophon franchise, disciplined financial execution and in FY27 we will progress the CORIS System from CMR to commercialisation.

What’s next for Nanosonics?

Looking ahead, Nanosonics expects continued revenue growth driven by its expanding trophon installed base, upgrades, and consumables and services. The commercial launch of CORIS is planned across the UK, Ireland and Australia in the first half of FY27, with the US to follow.

See also  Expert names 2 top ASX ETFs to buy today

The company has flagged a deliberate increase in operational expenses to support the CORIS commercialisation, but remains well-funded to pursue long-term opportunities. FY27 revenue guidance is between $220 million and $228 million (constant currency) with gross margin expected to moderate as new investments ramp up.

Nanosonics share price snapshot

Over the past 12 months, Nanosonics shares have declined 10%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement


Source link

Author

Shin John
Shin JohnYtv Market News
Share-market news writer and analyst with deep experience covering equities, commodities, forex, and cryptocurrencies for readers in the USA, UK, Canada, and Australia. Ytv Market News delivers timely market updates, practical trading insights, and clear explanations of macro and company-level catalysts that move prices. Combines on-the-ground financial reporting with technical analysis, using concise charts and actionable ideas to help investors and traders make smarter decisions.